STAT reports on the main questions facing the FDA following the end of the Overton era. The article outlines concerns about the agency’s next steps and the issues that may shape its future, according to STAT.
For pharma and biotech executives, the FDA’s direction affects drug development timelines, approval strategies and compliance risk. Shifts in regulatory focus could influence investment and R&D planning. Firms should watch for early signs of policy change.